Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
作者： Christoph Mamot , Dirk Klingbiel , Felicitas Hitz , Christoph Renner , Thomas Pabst
关键词:
摘要: Purpose Our main objective was to prospectively determine the prognostic value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after two cycles rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 14 days (R-CHOP-14) under standardized treatment PET evaluation criteria. Patients Methods with any stage diffuse large B-cell lymphoma were treated six R-CHOP-14 followed by rituximab. PET/CT examinations performed at baseline, (and four if patient PET-positive cycles), end treatment. evaluated locally central review. The primary point event-free survival 2 years (2-year EFS). Results Median age 138 evaluable patients 58.5 a WHO performance status 0, 1, or in 56%, 36%, 8% patients, respectively. By local assessment, 83 scans (60%) repo...
elsevier.com
sci-hub.se 参考文章(27)
Emmanuel Itti, Michel Meignan, Alina Berriolo-Riedinger, Alberto Biggi, Amanda F. Cashen, Pierre Véra, Hervé Tilly, Barry A. Siegel, Andrea Gallamini, René-Olivier Casasnovas, Corinne Haioun, An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 40, pp. 1312- 1320 ,(2013) , 10.1007/S00259-013-2435-6
Sandra J. Horning, Malik E. Juweid, Heiko Schöder, Gregory Wiseman, Alex McMillan, Lode J. Swinnen, Ranjana Advani, Randy Gascoyne, Andrew Quon, Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. ,vol. 115, pp. 775- 777 ,(2010) , 10.1182/BLOOD-2009-08-234351
John P. Klein, Brent Logan, Mette Harhoff, Per Kragh Andersen, Analyzing survival curves at a fixed point in time Statistics in Medicine. ,vol. 26, pp. 4505- 4519 ,(2007) , 10.1002/SIM.2864
René-Olivier Casasnovas, Michel Meignan, Alina Berriolo-Riedinger, Stéphane Bardet, Anne Julian, Catherine Thieblemont, Pierre Vera, Serge Bologna, Josette Brière, Jean-Philippe Jais, Corinne Haioun, Bertrand Coiffier, Franck Morschhauser, SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. ,vol. 118, pp. 37- 43 ,(2011) , 10.1182/BLOOD-2010-12-327767
G. Lenz, G. Wright, S.S. Dave, W. Xiao, J. Powell, H. Zhao, W. Xu, B. Tan, N. Goldschmidt, J. Iqbal, J. Vose, M. Bast, K. Fu, D.D. Weisenburger, T.C. Greiner, J.O. Armitage, A. Kyle, L. May, R.D. Gascoyne, J.M. Connors, G. Troen, H. Holte, S. Kvaloy, D. Dierickx, G. Verhoef, J. Delabie, E.B. Smeland, P. Jares, A. Martinez, A. Lopez-Guillermo, E. Montserrat, E. Campo, R.M. Braziel, T.P. Miller, L.M. Rimsza, J.R. Cook, B. Pohlman, J. Sweetenham, R.R. Tubbs, R.I. Fisher, E. Hartmann, A. Rosenwald, G. Ott, H.-K. Muller-Hermelink, D. Wrench, T.A. Lister, E.S. Jaffe, W.H. Wilson, W.C. Chan, L.M. Staudt, Stromal gene signatures in large-B-cell lymphomas The New England Journal of Medicine. ,vol. 359, pp. 2313- 2323 ,(2008) , 10.1056/NEJMOA0802885
Pierre-Yves Le Roux, Thomas Gastinne, Steven Le Gouill, Emmanuel Nowak, Caroline Bodet-Milin, Solène Querellou, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Pierre Yves Salaun, Françoise Bodere-Kraeber, Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 38, pp. 1064- 1071 ,(2011) , 10.1007/S00259-011-1741-0
Michel Meignan, Emmanuel Itti, Andrea Gallamini, Corinne Haioun, Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand? Leukemia & Lymphoma. ,vol. 50, pp. 1753- 1756 ,(2009) , 10.3109/10428190903308056
Patrizia Pregno, Annalisa Chiappella, Marilena Bellò, Barbara Botto, Simone Ferrero, Silvia Franceschetti, Francesca Giunta, Marco Ladetto, Giorgio Limerutti, Massimo Menga, Maura Nicolosi, Giorgio Priolo, Benedetta Puccini, Luigi Rigacci, Flavia Salvi, Luca Vaggelli, Roberto Passera, Gianni Bisi, Umberto Vitolo, Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. ,vol. 119, pp. 2066- 2073 ,(2012) , 10.1182/BLOOD-2011-06-359943
Bertrand Coiffier, Eric Lepage, Josette Brière, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht, CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma The New England Journal of Medicine. ,vol. 346, pp. 235- 242 ,(2002) , 10.1056/NEJMOA011795